PepGen Inc. (PEPG)
NASDAQ: PEPG · IEX Real-Time Price · USD
16.32
-1.59 (-8.88%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Company Description
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD.
PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.
PepGen Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | May 6, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Dr. James G. McArthur Ph.D. |
Contact Details
Address: 1 Marina Park Drive, Suite 900 Boston, Massachusetts 02210 United States | |
| Phone | 703-456-8000 |
| Website | pepgen.com |
Stock Details
| Ticker Symbol | PEPG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001835597 |
| CUSIP Number | 713317105 |
| ISIN Number | US7133171055 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James G. McArthur Ph.D. | President, Chief Executive Officer, Treasurer, Secretary and Director |
| Noel P. Donnelly M.B.A. | Chief Financial Officer |
| Niels Svenstrup Ph.D. | Senior Vice President of Chemistry, Manufacturing and Control |
| Dr. Michael Gait Ph.D. | Founder and Scientific Advisory Board Member |
| Mary Beth DeLena | General Counsel and Secretary |
| Dr. Michelle L. Mellion M.D. | Senior Vice President and Head of Clinical Development |
| Emiko Bryant | Chief of Staff |
| Kyle Breidenstine | Vice President of Finance and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2024 | 8-K | Current Report |
| Jun 28, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 20, 2024 | 8-K | Current Report |
| Jun 11, 2024 | 8-K | Current Report |
| Jun 5, 2024 | 144 | Filing |
| May 17, 2024 | 144 | Filing |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| May 1, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | ARS | Filing |